Bispecific T-cell engagers (BiTEs) are a class of engineered antibody-based immunotherapies designed to simultaneously bind the CD3 molecule on T-cells and a tumor-specific antigen, such as PSMA in PCa. This evidence concerns the gene FOLH1 and neoplasm.